Search Results
Jul 03, 2026, 18:40 ET Conformal Coatings Market worth $2.19 billion by 2031 - Exclusive Report by MarketsandMarkets™
Shin-Etsu Chemical Co., Ltd. (Japan), Dow Inc. (US), H.B. Fuller (US), Element Solutions Inc (ESI), ALTANA AG (Germany), Chase Corp. (US), Dymax (US), and MG Chemicals (Canada) are covered in the conformal coatings market. Partnerships, acquisitions, and expansions are some of the major strategies adopted
More news about: MarketsandMarkets
Jul 03, 2026, 06:02 ET 12 Top Press Releases from June
sleep apnea, demonstrating its remarkable potential to treat obesity and its complicationsIn TRIUMPH-1, participants on retatrutide 12 mg lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30, no longer meeting the BMI criteria for obesity.
More news about: PR Newswire
Jul 01, 2026, 21:00 ET Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC
third-generation, irreversible EGFR-TKI with proven clinical activity in EGFRm NSCLC, including against central nervous system metastases. Tagrisso (40mg and 80mg QD oral tablets) has been used to treat more than one million patients across its indications worldwide and AstraZeneca continues to explore Tagrisso
More news about: Abbisko
Jul 01, 2026, 16:06 ET Parceria entre Novo Nordisk e AS Medicamentos resulta no lançamento da NovoCare Farmácia, plataforma para compras online de medicamentos para obesidade e diabetes
relação aos tratamentos para diabetes, para apoiar na compra da semaglutida oral, na compra de duas caixas de qualquer dosagem de Rybelsus® (3 mg, 7 mg ou 14 mg), o custo mensal do tratamento sai por R$ 575,00 (e-commerce) ou R$ 625,00 (em lojas físicas). A condição é por tempo ilimitado.Para acessar
More news about: Novo Nordisk
Jul 01, 2026, 16:05 ET Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia
www.fda.gov/medwatch or call 1-800-FDA-1088.Dosage Forms and Strengths: CRENESSITY is available in 50 mg and 100 mg capsules, and as an oral solution of 50 mg/mL.Please see full
More news about: Neurocrine Biosciences, Inc.
Jul 01, 2026, 09:00 ET Oasis Launches Hemp-Derived Mixer
responsibility from every brand in the space."Each bottle delivers:Translucent, oil-free pour; quad-filtered10mg THC per serving; 170mg THC per bottleZero calories, zero sugar, zero carbsResealable child-resistant capDemand outpaced supply at
More news about: cbdMD, Inc.
Jul 01, 2026, 09:00 ET MetroPlusHealth Expands Gold Plan Benefits for New York City Employees and Families
medications, 25% increase of medications included compared to last yearThe newly expanded list of medications now includes ibuprofen 600mg, tretinoin, fluticasone nasal spray, and ketoconazole shampooReduced Gold pharmacy rider cost* for Individual and family coverageWellness
More news about: MetroPlusHealth
Jul 01, 2026, 08:59 ET Charles Huang: The True Meaning of Business Success Is Giving Back
several international strategic partnerships involving major Chinese private enterprises, including efforts to facilitate collaboration with the UK's MG Rover Group. Although the transaction ultimately did not conclude because of changes in corporate ownership, the experience reinforced his belief that
More news about: Pasaca Capital Inc.
Jul 01, 2026, 08:39 ET Juni Reimagines Summer's Favorite Drink with New Functional Lemonade Trio
ingredients and a natural source of antioxidants, including ashwagandha, lion's mane, reishi mushroom, green tea and acerola cherry. Crafted with zero sugar, 30mg of caffeine, and USDA Organic certified ingredients, Juni offers a refreshing sparkling tea made for sunny days, social moments, and alcohol-free occasions. "We're
More news about: Juni
Jul 01, 2026, 08:39 ET Kollo Health Launches FLEX+ Advanced Joint Support Featuring AprèsFlex®
improvements in joint comfort and physical function within just five days. The ingredient is also notable for its low clinically studied dose of only 100 mg per day, making it one of the most efficient joint health support ingredients available to formulators.Across four randomized, placebo-controlled
More news about: PLT Health Solutions, Inc.
Jul 01, 2026, 08:36 ET Cyclone Pods Publishes Raw, Sample-by-Sample Lab Data for Its Nicotine-Free Vapes and Pouches
and $14 per pod. Focus Pouches, at $9.99 for a 20-count, contain ashwagandha, lion's mane, reishi, cordyceps, bacopa monnieri and guarana providing 50 mg of caffeine.The full laboratory results are available to journalists at
More news about: Cyclone Pods
Jul 01, 2026, 07:00 ET Wegovy® is now accessible to eligible Medicare beneficiaries living with obesity through Medicare GLP-1 Bridge
medical care of patients with obesity. Endocr Pract. 2016;22 (Suppl 3):1–203.Wharton S, Lingvay I, Bogdanski P, et al. Oral semaglutide 25 mg in adults with overweight or obesity. N Engl J Med. 2025; 393:1077-1087. DOI: 10.1056/NEJMoa2500969.Centers for Disease Control and Prevention.
More news about: Novo Nordisk
Jul 01, 2026, 06:00 ET INVESTOR ALERT: Erasca, Inc. (ERAS) Investors with Substantial Losses Have Opportunity to Lead the Erasca Class Action Lawsuit
after market close on April 27, 2026, Erasca reported preliminary Phase I clinical data for ERAS-0015 and disclosed that one patient who received 24 mg of ERAS-0015 had died approximately one month after starting ERAS-0015. Erasca allegedly further disclosed that comparisons between ERAS-0015
More news about: Robbins Geller Rudman & Dowd LLP
Jun 30, 2026, 16:19 ET Apotex first to receive Health Canada approval for SEVMIA™, a generic semaglutide for chronic weight management
SEVMIA™ (semaglutide injection) is supplied as a multi-use pre-filled pen delivering doses of 1 mg (4 mg per pen; 1.34 mg/mL).This approval follows Health Canada's recent approval of Apo‑Semaglutide Injection™, and reflects Apotex's continued focus on bringing
More news about: Apotex Inc.
Jun 30, 2026, 08:36 ET BLNCD Naturals and Foundry Nation Introduce New .4mg THC Beverage Collection
Mocktail 0.4mg THC, 10mg CBG, and Sativa Terpenes.Brain Boost Functional Cannabis Elixir0.4mg THC, 10mg CBG, Lion's Mane, Rhodiola, Ashwagandha, Agave Inulin and Sativa Terpenes.Zen Blend Functional Cannabis Elixir0.4mg THC, 10mg CBD, Reishi, Chaga,
More news about: BLNCD
Jun 30, 2026, 07:30 ET Biohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 Activator
is ongoing and has identical entry criteria and endpoints with a 12-week double-blind treatment period and evaluates opakalim 25 mg and 50 mg once-daily in Part A and 75 mg once-daily in Part B.In May 2026, at its R&D Day, Biohaven showcased evidence supporting the promise of opakalim to address
More news about: Biohaven Ltd.
Jun 30, 2026, 07:00 ET Affron® Saffron to Help Improve Mood, Self-Esteem in Adult Women
Adrian Lopresti, PhD enrolled 86 women aged 50–70 years experiencing low mood and poor sleep. Participants were randomly assigned to receive either 28 mg of Affron® saffron daily or an identical looking placebo. They completed a series of validated self-report questionnaires before, during, and after the
More news about: Pharmactive Biotech Products, S.L.U.
Jun 29, 2026, 16:52 ET AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
since DLBCL diagnosis. Patients received subcutaneous epcoritamab (cycles 1–3, once weekly; cycles 4–12, once every 4 weeks) and oral lenalidomide (25 mg/day on days 1–21) for a total of twelve 28-day cycles or intravenously infused R-GemOx for up to four cycles (each cycle lasting 28 days). The trial
More news about: AbbVie
Jun 29, 2026, 16:15 ET AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
since DLBCL diagnosis. Patients received subcutaneous epcoritamab (cycles 1–3, once weekly; cycles 4–12, once every 4 weeks) and oral lenalidomide (25 mg/day on days 1–21) for a total of twelve 28-day cycles or intravenously infused R-GemOx for up to four cycles (each cycle lasting 28 days). The trial
More news about: AbbVie
Jun 29, 2026, 15:20 ET Lifeway® Foods' Farmer Cheese Selected as a Good Housekeeping 2026 Snack Awards Winner
and overall wellness, its nutrient-rich profile includes 12 live and active probiotic cultures, 15 grams of high-quality, bioavailable protein and 120mg of calcium per serving. Farmer Cheese is also lactose intolerance-friendly, gluten free and naturally low in sodium with no added salt or sugar, making
More news about: Lifeway Foods, Inc.
Jun 29, 2026, 13:30 ET Plopii lanza sobres nootrópicos para la concentración sin nicotina, potenciados con paraxantina
concentración, con un perfil más suave para el sueño, la ansiedad y la tolerancia.La fórmula combina paraxantina con 60 mg de alfa-GPC, 60 mg de citicolina y 60 mg de L-teanina, una combinación diseñada para favorecer la atención y una energía tranquila y concentrada durante todo el día."Creamos
More news about: Plopii Inc.
Jun 29, 2026, 13:28 ET Plopii bringt nikotinfreie „Focus"-Beutel mit nootropischer Wirkung auf den Markt, deren Wirkstoff Paraxanthin ist
milderen Auswirkungen auf den Schlaf, die Angstempfindung und die Toleranzentwicklung.Die Formel kombiniert Paraxanthin mit 60 mg Alpha-GPC, 60 mg Citicolin und 60 mg L-Theanin – eine Kombination, die darauf ausgelegt ist, die Aufmerksamkeit sowie eine ruhige, konzentrierte Energie über den ganzen
More news about: Plopii Inc.
Jun 29, 2026, 12:21 ET Plopii lance des sachets « Focus » nootropiques sans nicotine, à base de paraxanthine
un profil d'action plus doux en matière de sommeil, d'anxiété et de tolérance.Cette formule associe la paraxanthine à 60 mg d'Alpha-GPC, 60 mg de citicoline et 60 mg de L-théanine, une combinaison conçue pour favoriser la concentration et procurer une énergie sereine et ciblée tout au long de
More news about: Plopii Inc.
Jun 29, 2026, 11:13 ET Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression
Optimi's 5mg psilocybin capsules are prescribed in Australia for treatment-resistant depression.The export marks Optimi's third commercial shipment since launching the 5mg psilocybin capsules in September 2025.VANCOUVER, BC,
More news about: Optimi Health Corp
Jun 29, 2026, 10:41 ET Plopii Launches Nootropic Nicotine-Free Focus Pouches Powered by Paraxanthine
energy and clearer focus with a gentler profile for sleep, anxiety, and tolerance.The formula pairs paraxanthine with 60mg of Alpha-GPC, 60mg of Citicoline, & 60mg of L-theanine, a combination designed to support attention and calm, focused energy throughout the day."We built Plopii
More news about: Plopii Inc.